Remembering Trump's Bold Move: The 100% Tariff Threat on Pharmaceuticals

Takeda Announces Significant Job Cuts, Centered on Cambridge R&D

A Child's Battle, An Insurance Denial: Mark Cuban Highlights Healthcare's Heartbreaking Flaws

The Drumbeat Builds: Milestone Pharma Prepares for Q4 Earnings Reveal

A Game-Changer: Boost Pharma Welcomes Biotech Visionary Elaine Jones as New Board Chair

The Persistent Echo: Trump's Most Favored Nation Policy Still Shapes Drug Pricing Debates

The Future of Medicine: Unlocking Potential with Organoids and Spheroids

A Wake-Up Call for Big Pharma: FDA Cracks Down on Novo Nordisk

The Maverick Doctor Poised to Redefine Public Health in America

The Shadow of Geopolitics: Indian Pharma Exports to Middle East Face Uncertainty Amidst Rising Tensions

The Price of Life: Will South Africa Gain Access to Gilead's Breakthrough HIV Drug?

A Hard-Won Victory: Henrietta Lacks' Estate Secures Settlement with Novartis

A Critical Heads-Up for Ultragenyx (RARE) Investors: Understanding Your Rights in the Securities Class Action

The Cost of Cures: Unpacking the Price Tag of Novo Nordisk's Breakthrough Drugs in America

Taro Pharmaceuticals: A Bladder Cancer Setback Sparks a 15% After-Hours Slide – Is This a Buy-the-Dip Moment or a Sign of Deeper Trouble?

Unveiling the Truth: Are FDA Drug Studies Truly Robust?

Under the Microscope: Reassessing the Foundations of Our Medicines

Moderna's Ambitious mRNA Flu Vaccine Hits a Regulatory Snag

The Prescription Revolution: How Amazon is Reshaping Medicine Delivery

Novo Nordisk Doubles Down: Lawsuit Against Hims & Hers Continues Despite 'Wegovy Pill' Plans Scrapped

Weight-Loss Drug Wars Escalate: Novo Nordisk Sues Hims & Hers Over Compounded Semaglutide

The Weight-Loss Revolution: Telehealth Giant Hims & Hers Dives into the GLP-1 Market

Trump Launches TrumpRx: A Digital Crusade Against Sky-High Drug Prices

The Shifting Sands of US Drug Pricing: Why Big Pharma Investors are on Edge

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

Navigating Choppy Waters: Three Healthcare Stocks Facing Significant Headwinds This Quarter

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

The Unsung Heroes of Biotech: How Biological Buffers Are Fueling a $2.39 Billion Revolution

Big Pharma Breaks Silence: Confronting RFK Jr. on Vaccines

The Great Healthcare Comeback: How Clarity on Pricing and Tariffs Stabilized a Shaken Sector

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

Bristol Myers Squibb: Navigating the Patent Storm, Still a Cash Machine?

A Seismic Shift Brewing? Cannabis Stocks Soar on Trump's Marijuana Rescheduling Hints

Navigating the Complex Currents of Modern Pharmaceuticals

A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

A Landmark Win for Innovation: Delhi High Court Upholds Novo Nordisk's Semaglutide Patent